

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 February 2023 (16.02.2023)



(10) International Publication Number
WO 2023/019241 A3

- (51) **International Patent Classification:**
A61K 39/39 (2006.01) *A61P 25/28* (2006.01)
- (21) **International Application Number:**
PCT/US2022/074902
- (22) **International Filing Date:**
12 August 2022 (12.08.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/260,227 12 August 2021 (12.08.2021) US
63/263,541 04 November 2021 (04.11.2021) US
63/267,975 14 February 2022 (14.02.2022) US
- (71) **Applicants:** JANSSEN PHARMACEUTICALS, INC. [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (US). **AC IMMUNE SA** [CH/CH]; EPFL Innovation Park, Building B, 1015 Lausanne (CH).
- (72) **Inventors:** **PFEIFER, Andrea**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH). **MUHS, Andreas**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH). **GALPERN, Wendy**; c/o Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (US).
- (74) **Agent:** **ICE MILLER LLP** et al.; Weihong, Hsing, J., D., 1735 Market Street, Suite 3900, Philadelphia, PA 19103-7509 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** LIPOSOMES CONTAINING PHOSPHORYLATED TAU PEPTIDES FOR INDUCING SUSTAINED IMMUNE RESPONSES




FIG. 1

(57) **Abstract:** Methods for inducing a sustained immune response against phosphorylated Tau in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist, a helper T-cell epitope, a lipidated CpG oligonucleotide, and a Tau phosphopeptide presented on the surface of the liposome to thereby obtain the sustained immune response.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

23 March 2023 (23.03.2023)